Day: November 13, 2023
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
- PBGENE-HBV designed to both eliminate cccDNA and inactivate HBV DNA - Data demonstrates strong proof of concept efficacy including up to 99% viral engagement and no detectable off-target editing at maximal on-target editing dose - PBGENE-HBV final clinical candidate ready with CTA and/or IND